Cargando…
Nebulised 3% hypertonic saline versus 0.9% saline for treating patients hospitalised with acute bronchiolitis: protocol for a randomised, double-blind, multicentre trial
INTRODUCTION: Bronchiolitis is an acute viral infection of the lower respiratory tract. It is most commonly caused by respiratory syncytial virus. Being a common reason for hospitalisation, it affects 13–17% of all hospitalised children younger than 2 years. Only supportive therapy, including suctio...
Autores principales: | Szupieńko, Sara, Buczek, Aleksandra, Szymański, Henryk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685959/ https://www.ncbi.nlm.nih.gov/pubmed/38011984 http://dx.doi.org/10.1136/bmjopen-2023-080182 |
Ejemplares similares
-
SABRE: a multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis
por: Everard, Mark L, et al.
Publicado: (2014) -
Nebulised hypertonic saline (3 %) among children with mild to moderately severe bronchiolitis - a double blind randomized controlled trial
por: Khanal, Aayush, et al.
Publicado: (2015) -
Comparison of nebulised 3% hypertonic saline with ipratropium bromide in treatment of children with bronchiolitis: a randomized control trial
por: Naveed, Hina, et al.
Publicado: (2023) -
The cost-effectiveness of hypertonic saline inhalations for infant bronchiolitis
por: Buendía, Jefferson Antonio, et al.
Publicado: (2020) -
Hypertonic saline (HS) for acute bronchiolitis: Systematic review and meta-analysis
por: Maguire, Chin, et al.
Publicado: (2015)